# metabolic dysfunction-associated steatohepatitis (MASH) - minimax-m3

- Benchmark system: raw
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 4075
- Completion tokens: 7716
- Reasoning tokens: 
- Total tokens: 11791
- API requests reported: 
- Elapsed seconds: 255.083
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: MiniMax

---
<think>The user wants me to perform a multidimensional, evidence-grounded interpretation of transcriptomic data comparing MASH/NASH liver tissue vs healthy controls. Let me analyze the input data carefully.

Let me organize the genes by direction:

**Upregulated genes (positive log2FC):**
- UQCRBP1 (3.73) - likely mitochondrial/ubiquinol-cytochrome c reductase binding protein pseudogene
- SNORD140 (3.06) - small nucleolar RNA
- LOC105377700 (3.93) - lncRNA
- MIR4647 (2.53) - microRNA
- UBD (4.15) - Ubiquitin D, also known as FAT10
- DTNA (3.72) - Dystrobrevin alpha
- TP53I3 (3.26) - Tumor protein p53 inducible protein 3
- LOC107984754 (3.64) - lncRNA
- CIMIP2A (2.48)
- DYNLT1 (1.52) - Dynein light chain Tctex-type 1
- AJUBA (1.92) - Ajuba LIM protein
- MIR12136 (3.18)
- TMEM154 (3.71)
- TREM2 (4.91) - Triggering receptor expressed on myeloid cells 2 - KEY macrophage/Kupffer cell marker
- TRNK (2.73) - mitochondrial tRNA
- MRPL1-AS1 (2.77)
- EME1 (1.88)
- CYCS (1.56) - Cytochrome c, somatic - apoptosis/mitochondrial
- TRNS1 (3.05)
- DUSP8 (3.49) - Dual specificity phosphatase 8
- TSC22D1 (1.45)
- GGTLC1 (2.33)
- MIR4426 (2.24)
- MIR1244-1 (1.39)
- KCNJ5 (2.69)
- FABP5 (2.85) - Fatty acid binding protein 5
- TRNC (4.07) - mitochondrial tRNA
- CAST (4.02) - Calpastatin
- LINC01485 (2.11)
- PFDN6 (1.49)
- CXCL10 (3.46) - chemokine, immune/inflammation
- TNFRSF12A (3.27) - also known as Fn14, TWEAK receptor
- LOC105371873 (3.82)
- MIR1825 (1.83)
- TIMM17A (1.28) - mitochondrial
- MIR4721 (1.74)
- MTHFD1L (1.72) - mitochondrial folate enzyme
- RPSA2 (1.22)
- RPL9 (1.47)
- CES1P2 (1.77)
- TRNL2 (3.86)
- CAPG (2.57) - macrophage actin regulator
- S100A14 (1.78)
- GUSBP2 (2.63)
- TRNY (3.57)
- FOXM1 (2.14) - transcription factor, proliferation
- MACROH2A2 (1.63)
- LSMEM2 (1.30)
- HS3ST2 (3.72)
- MTRNR2L8 (3.25)
- MANF (1.85) - mesencephalic astrocyte-derived neurotrophic factor, UPR/ER stress

**Downregulated genes (negative log2FC):**
- CD81-AS1 (-2.96)
- MS4A6E (-3.52) - macrophage marker, but downregulated here
- MARCO (-2.84) - Macrophage receptor with collagenous structure - IMPORTANT Kupffer cell marker
- VCAM1 (-2.38) - Vascular cell adhesion molecule
- GLUD1P2 (-1.94)
- CR1 (-3.61) - Complement receptor 1
- FGFRL1 (-1.49)
- CD163 (-2.52) - Macrophage scavenger receptor - IMPORTANT
- LYVE1 (-2.73) - Lymphatic vessel endothelial hyaluronan receptor 1 - macrophage/LSEC marker
- P4HA1 (-3.19) - Prolyl 4-hydroxylase subunit alpha 1
- P2RY13 (-2.10) - Kupffer cell marker
- SPIC (-2.62)
- LOC107986183 (-3.64)
- PCDH20 (-4.59)
- TIMD4 (-4.28) - Kupffer cell specific marker, phosphatidylserine receptor
- ETV5 (-1.93)
- MRC1 (-2.10) - Mannose receptor C type 1, CD206 - M2 macrophage marker
- CDH23 (-1.90)
- CFP (-1.86) - Complement factor properdin
- CETP (-2.49)
- NUCB1-AS1 (-1.86)
- MIR6717 (-2.24)
- TINAGL1 (-1.78)
- FNBP1 (-1.12)
- MAST1 (-2.73)
- CD5L (-2.90) - CD5 molecule like - macrophages
- MPEG1 (-1.74) - Macrophage expressed gene 1
- SIGLEC1 (-2.12) - Sialic acid binding Ig like lectin 1
- MROH2B-DT (-1.73)
- NDST3 (-2.67)
- SIGLEC11 (-2.12)
- CBS (-1.25) - Cystathionine beta synthase - H2S/homocysteine metabolism
- TCF7L1 (-1.53)
- CD209 (-2.43) - DC-SIGN
- PDE2A (-1.63)
- HCFC1 (-1.25)
- LDB2 (-1.53)
- CSF1R (-1.98) - Macrophage colony stimulating factor receptor - KEY macrophage marker
- FOLR2 (-2.04) - Folate receptor beta - macrophage marker
- SEC14L1 (-1.36)
- LOC102724560 (-1.27)
- RASL10B (-2.57)
- SCLY (-1.28)
- LOC107986158 (-1.74)
- CDH5 (-1.38) - VE-cadherin, endothelial
- HSPA9-AS1 (-1.82)
- CNPY3-GNMT (-1.76)
- PLXNB2 (-1.18)

Let me think about the major biological themes:

**1. Macrophage/Kupffer cell biology - mixed signals:**
UP: TREM2 (very strong - log2FC 4.91), CXCL10, CAPG, FABP5
DOWN: MARCO, CD163, LYVE1, P2RY13, TIMD4, MRC1, CD5L, MPEG1, CSF1R, FOLR2, CD209, SIGLEC1, SPIC, MS4A6E

This is very interesting - it suggests a shift in macrophage populations:
- TREM2 is a marker of lipid-associated macrophages (LAMs) / NASH-associated macrophages (NAMs)
- The downregulation of MARCO, CD163, TIMD4, LYVE1, CSF1R, MRC1 suggests depletion of resident Kupffer cells
- CXCL10 is a pro-inflammatory chemokine
- TREM2+ macrophages are well-characterized in NASH/MASH

**2. Mitochondrial dysfunction:**
UP: UQCRBP1 (mitochondrial complex III), CYCS, TIMM17A, MTHFD1L, MANF, TRNK, TRNS1, TRNL2, TRNC, TRNY
- Many mitochondrial tRNAs upregulated
- MANF is ER stress/UPR related but also mitochondrial-protective
- CYCS - cytochrome c, apoptosis
- UQCRBP1 is interesting - pseudogene

**3. Inflammation/chemotaxis:**
UP: CXCL10, TNFRSF12A (Fn14), FABP5
- CXCL10 - interferon-γ-inducible chemokine, T cell recruitment
- TNFRSF12A - TWEAK receptor, implicated in liver inflammation/fibrosis
- FABP5 - fatty acid metabolism in immune cells

**4. Cell adhesion/ECM:**
DOWN: VCAM1 (paradoxical - usually increased in inflammation), CDH5 (endothelial), PLXNB2
UP: DTNA, PCDH20 (down actually)

**5. ER stress/UPR:**
UP: MANF, TRNK (mitochondrial tRNA)
- MANF is UPR-regulated

**6. Complement/coagulation:**
DOWN: CR1, CFP, CETP

**7. Cell proliferation:**
UP: FOXM1

**8. tRNA metabolism:**
UP: Multiple mitochondrial tRNAs (TRNK, TRNS1, TRNL2, TRNC, TRNY)
- This is unusual - could indicate mitochondrial stress response

**9. Apoptosis:**
UP: CYCS, TP53I3

Let me think about the macrophage biology more carefully:

In MASH, the paradigm is:
- Loss of embryonically-derived resident Kupffer cells (MARCO+, TIMD4+, CLEC4F+)
- Replacement by monocyte-derived macrophages
- Specifically, TREM2+CD9+ lipid-associated macrophages (LAMs) accumulate
- These LAMs are pro-inflammatory and pro-fibrotic

The data strongly support this paradigm:
- DOWN of MARCO, TIMD4, LYVE1, CLEC2D-like (CSF1R, MRC1, CD163, CD5L) - resident KC markers
- UP of TREM2 - hallmark of monocyte-derived LAMs

This is a very clean signal for "macrophage remodeling" in MASH.

**Other programs:**

2. **Mitochondrial stress/dysfunction:**
- Multiple mitochondrial tRNAs upregulated (unusual)
- CYCS upregulation (apoptosis indicator)
- MANF upregulation (protective UPR response)
- MTHFD1L - mitochondrial folate metabolism
- This could reflect mitochondrial damage and compensatory response

3. **Inflammatory signaling/CXCL10 axis:**
- CXCL10 - strong upregulation, classic MASH/NASH inflammatory chemokine
- TNFRSF12A/Fn14 - receptor for TWEAK, promotes fibrosis
- These are well-established MASH mediators

4. **Oxidative stress/DNA damage response:**
- TP53I3 - p53 target, oxidative stress response
- FOXM1 - proliferation/DNA repair
- EME1 - DNA repair (interstrand crosslink)

5. **Endothelial/sinusoidal remodeling:**
- CDH5 down - VE-cadherin, sinusoidal endothelial dysfunction
- LYVE1 down - LSEC marker
- VCAM1 down - paradox, since usually increased... but could be due to endothelial damage or specific cell loss

Let me think about key genes for deeper discussion:

**Top key genes/modules:**
1. TREM2 - most upregulated, central to macrophage remodeling paradigm
2. MARCO - most downregulated KC marker
3. TIMD4 - strongest downregulated KC marker (log2FC -4.28)
4. CXCL10 - inflammatory chemokine
5. TNFRSF12A/Fn14 - TWEAK receptor, fibrogenic
6. CYCS - mitochondrial, apoptosis
7. MANF - ER/UPR stress response, protective
8. CSF1R - macrophage differentiation, downregulated (loss of resident KC)
9. CD163 - KC marker, downregulated
10. UBD/FAT10 - ubiquitin-like modifier, implicated in NASH

Let me think about UBD:
- UBD (Ubiquitin D) is a ubiquitin-like modifier
- Known to be highly induced by IFN-γ and TNF-α
- Has been implicated in NASH pathogenesis
- Drives immune activation and apoptosis

**Validation priorities:**

1. TREM2+ macrophage accumulation - biomarker/therapeutic target
   - Strong literature support
   - Could be biomarker for disease activity
   - Therapeutic targets in development (e.g., anti-TREM2 antibodies in NASH trials)

2. Resident Kupffer cell depletion (MARCO/TIMD4/CD163 loss)
   - Important for understanding disease mechanism
   - Could indicate replacement dynamics

3. CXCL10/CXCR3 axis - therapeutic target
   - CXCL10 antagonism in clinical trials for various inflammatory diseases

4. TNFRSF12A (Fn14) - therapeutic target
   - Anti-TWEAK antibodies in development for liver disease
   - Promotes fibrogenesis

5. Mitochondrial dysfunction - mechanistic hypothesis
   - Multiple mitochondrial genes suggest broad mitochondrial stress

**Limitations:**

1. Tissue composition - changes in Kupffer cell vs monocyte-derived macrophage ratios could drive many signals. Without single-cell deconvolution, can't distinguish cell-type-specific changes from compositional shifts.

2. Disease stage heterogeneity - MASH has stages (early inflammatory vs fibrotic)

3. Many genes are uncharacterized lncRNAs, snoRNAs, miRNAs - hard to interpret

4. The mitochondrial tRNA upregulation is unusual - could be technical artifact or genuine mitochondrial stress response

5. Some genes (UQCRBP1, CES1P2, GUSBP2) are pseudogenes

6. The opposing direction of MARCO (down) and TREM2 (up) is consistent with cell composition shifts, but the magnitude needs to be verified

Let me now write the response. I need to be careful about:
- Being evidence-grounded
- Not overstating causal relationships
- Distinguishing direct evidence from the dataset vs external literature
- Clearly noting limitations
- Focusing on biologically meaningful programs

Let me draft the response now.

I should format this clearly with sections matching the requirements.</think>

# Transcriptomic Interpretation: MASH/NASH vs Healthy Liver

## 1. Overall Biological Interpretation

The transcriptomic signature of MASH versus healthy liver tissue is dominated by **two converging biological programs**: (a) a **profound remodeling of the hepatic macrophage compartment**, characterized by loss of embryonically derived Kupffer cell identity and emergence of monocyte-derived lipid-associated macrophages; and (b) a **mitochondrial stress/inflammatory injury program**, reflected by co-upregulation of cytochrome c, multiple mitochondrial tRNAs, mitochondrial folate metabolism, and the UPR-protective factor MANF.

These changes are accompanied by a secondary **interferon/CXCL10-driven inflammatory chemokine program** and signals of **fibrogenic priming via TNFRSF12A (Fn14)**. Downregulation of sinusoidal endothelial markers (CDH5, LYVE1) and complement genes (CR1, CFP) suggests **sinusoidal capillarization and loss of innate immune homeostasis**. Many of the most strongly differentially expressed genes are uncharacterized lncRNAs, snoRNAs, miRNAs, and pseudogenes, whose contributions should be interpreted with caution. The overall signature is biologically coherent and consistent with the modern understanding of NASH pathogenesis, but a substantial fraction of the signal likely reflects cell-compositional shifts rather than cell-intrinsic transcriptional change.

---

## 2. Core Biological Programs

### Program 1 — Hepatic Macrophage Remodeling (TREM2-high / resident-KC-low)
- **Direction:** Coordinated — TREM2+ monocyte-derived macrophages expanded; MARCO+/TIMD4+/CD163+/LYVE1+/CSF1R+ resident Kupffer cell identity depleted.
- **Supporting genes (UP):** **TREM2** (log2FC +4.91), **CXCL10** (+3.46), **CAPG** (+2.57), **FABP5** (+2.85), **MS4A6E** (note: here downregulated, see below).
- **Supporting genes (DOWN):** **MARCO** (−2.84), **TIMD4** (−4.28), **CD163** (−2.52), **LYVE1** (−2.73), **CSF1R** (−1.98), **MRC1/CD206** (−2.10), **CD5L** (−2.90), **P2RY13** (−2.10), **FOLR2** (−2.04), **MPEG1** (−1.74), **SIGLEC1** (−2.12), **CD209** (−2.43), **SPIC** (−2.62), **MS4A6E** (−3.52), **CR1** (−3.61).
- **Best pathway annotations:** Hallmark *Inflammatory Response*; Reactome *Innate Immune System*; cell-type marker gene sets for *Kupffer cells (MARCO-high)* and *TREM2+ lipid-associated macrophages (LAMs/NAMs)* from scRNA-seq atlases (Ramachandran, Remmerie, et al.).
- **Why this program:** The directionality across ~15 independent resident-KC markers vs the monocyte-derived LAM hallmark TREM2 is internally consistent with the established paradigm in which embryonically derived Kupffer cells (Tim4+, Marco+, Clec4f+) contract in NASH and are replaced by bone-marrow-derived TREM2+/CD9+ macrophages that surround crown-like structures.
- **Strength:** Strong. Multiple independent resident-KC markers move in the same direction and a single canonical LAM marker moves in the opposite direction.
- **Limitations:** Bulk tissue cannot distinguish cell-intrinsic gene regulation from changes in the relative abundance of cell populations. The dataset does not include matched single-cell RNA-seq to confirm the population shift.

### Program 2 — Mitochondrial Injury and Apoptotic Priming
- **Direction:** Coordinated upregulation of mitochondrial transcripts and pro-apoptotic factors.
- **Supporting genes (UP):** **CYCS** (cytochrome c, somatic, +1.56), **MTHFD1L** (+1.72, mitochondrial folate cycle), **TIMM17A** (+1.28, mitochondrial translocase), **UQCRBP1** (+3.73, mitochondrial complex III–related pseudogene), **TRNK / TRNS1 / TRNL2 / TRNC / TRNY** (multiple mitochondrial tRNAs, log2FC +2.7 to +4.1), **TP53I3** (+3.26, p53 oxidative-stress target), **MANF** (+1.85, mesencephalic astrocyte-derived neurotrophic factor, UPR/ER-stress and mitochondrial-protective).
- **Best pathway annotations:** KEGG *Oxidative phosphorylation*, *Apoptosis*; Reactome *Mitochondrial translation*, *Respiratory electron transport*; Hallmark *Reactive Oxygen Species Pathway*.
- **Why this program:** Mitochondrial tRNA induction (rather than repression) is atypical; combined with CYCS elevation and TP53I3 induction, this most plausibly reflects compensatory mitochondrial biogenesis/translation in response to lipotoxic mitochondrial damage. MANF upregulation is consistent with UPR engagement that is commonly seen in MASH hepatocytes.
- **Strength:** Moderate. Many of the mitochondrial tRNA signals are unusual, and one of the strongest hits (UQCRBP1) is a pseudogene of unclear functional relevance.
- **Limitations:** Mitochondrial tRNA "upregulation" may partly reflect mitochondrial DNA copy-number variation between samples, a known confounder in bulk RNA-seq of steatotic liver.

### Program 3 — Inflammatory Chemokine / Interferon Signaling
- **Direction:** Upregulated.
- **Supporting genes:** **CXCL10** (log2FC +3.46), **TNFRSF12A/Fn14** (+3.27), **UBD/FAT10** (+4.15), **S100A14** (+1.78), **FABP5** (+2.85).
- **Best pathway annotations:** Hallmark *Interferon Gamma Response*; Reactome *Chemokine receptors bind chemokines*; GO *cellular response to interferon-gamma*.
- **Why this program:** CXCL10 is the canonical IFN-γ–induced chemokine and a well-documented MASH biomarker; UBD (FAT10) is itself strongly IFN-γ/TNF-α inducible. TNFRSF12A is the receptor for TWEAK and a known driver of hepatocyte injury and hepatic stellate cell activation. The co-occurrence of these genes is consistent with a Th1/interferon-polarized inflammatory milieu.
- **Strength:** Strong at the gene level; CXCL10 and UBD are independent IFN-induced genes, providing genuinely independent evidence.
- **Limitations:** Bulk expression conflates the cellular source (hepatocytes vs immune vs endothelial cells).

### Program 4 — Fibrogenic / Tissue-Remodeling Priming
- **Direction:** Mixed — upregulation of fibrogenic receptor TNFRSF12A and ECM/lipid-binding protein FABP5; downregulation of selected endothelial and basement-membrane genes.
- **Supporting genes:** **TNFRSF12A** (Fn14, +3.27), **FABP5** (+2.85), **AJUBA** (+1.92, Hippo/Wnt signaling), **FOXM1** (+2.14, proliferation/fibrosis); downregulated **CDH5** (VE-cadherin, −1.38), **VCAM1** (−2.38), **LDB2** (−1.53), **PLXNB2** (−1.18), **P4HA1** (−3.19).
- **Best pathway annotations:** KEGG *TGF-beta signaling*, *Focal adhesion*; Reactome *Non-integrin membrane-ECM interactions*.
- **Why this program:** Fn14 is a TWEAK receptor that activates NF-κB and promotes HSC survival/fibrogenesis. Loss of CDH5 and LYVE1 is consistent with sinusoidal capillarization — a recognized feature of progressive MASH. P4HA1 loss is harder to interpret in isolation.
- **Strength:** Moderate. VCAM1 downregulation is somewhat paradoxical (it is usually increased in inflamed liver) and may reflect endothelial cell loss rather than transcriptional repression.
- **Limitations:** No first-tier fibrogenic collagens (COL1A1, COL3A1, ACTA2) appear at the top of the differential list, so direct fibrogenic activation cannot be confirmed from this gene set alone.

### Program 5 — Complement and Innate Immune Homeostasis Loss
- **Direction:** Downregulated.
- **Supporting genes:** **CR1** (−3.61), **CFP** (properdin, −1.86), **CETP** (−2.49).
- **Best pathway annotations:** Reactome *Complement cascade*; KEGG *Complement and coagulation cascades*.
- **Why this program:** The coordinate loss of complement receptor/regulator transcripts is consistent with the disappearance of resident Kupffer cells (which are major complement-clearing cells in liver sinusoids) and may contribute to impaired clearance of immune complexes in MASH.
- **Strength:** Weak to moderate (only 3 genes, none are core pathway drivers).
- **Limitations:** This is a small program and may be a downstream consequence of Program 1 rather than an independent axis.

---

## 3. Key Genes and Interaction Modules (≤10)

1. **TREM2** — log2FC +4.91 (UP). The single most upregulated gene. Hallmark of monocyte-derived lipid-associated macrophages (LAMs/NAMs); mechanistically linked to lipid sensing, foam-cell formation, and crown-like structures in NASH. Co-expressed (not directly interacting) with FABP5, CXCL10, and CAPG in the LAM transcriptional module. Independent scRNA-seq evidence places TREM2 at the center of the MASH macrophage module.

2. **MARCO** — log2FC −2.84 (DOWN). Canonical tissue-resident Kupffer cell marker. Its downregulation alongside TIMD4, CD163, LYVE1, and CSF1R indicates loss of embryonically derived Kupffer cells. Relationship to TREM2: co-membership in opposing cell-population modules (anti-correlated at the population level, not at the single-cell level).

3. **TIMD4** — log2FC −4.28 (DOWN, the strongest individual down signal). Tim-4 is the most specific marker of embryonically derived, self-maintaining Kupffer cells; its near-complete loss strongly supports a fundamental Kupffer cell compartment collapse in MASH.

4. **CXCL10** — log2FC +3.46 (UP). The dominant chemokine signal; a well-validated NASH biomarker in human cohorts. Acts via CXCR3 to recruit Th1 and NK cells. Co-expressed with TREM2 and UBD (pathway co-membership in interferon response), not a direct physical interactor.

5. **TNFRSF12A (Fn14)** — log2FC +3.27 (UP). Receptor for TWEAK; promotes hepatocyte apoptosis and HSC activation. Direct physical interaction with TWEAK (TNFSF12). Pharmacologically tractable.

6. **UBD (FAT10)** — log2FC +4.15 (UP). Ubiquitin-like modifier, strongly IFN-γ/TNF-α–induced. Implicated in hepatocellular apoptosis and MASH progression in published models. No direct physical interaction with TREM2 or CXCL10 — co-expression in interferon/inflammation module.

7. **CYCS** — log2FC +1.56 (UP). Cytochrome c; mitochondrial apoptotic priming. Direct physical interaction within the mitochondrial respiratory chain and with APAF-1 in the apoptosome.

8. **MANF** — log2FC +1.85 (UP). UPR- and ER-stress–responsive neurotrophic factor with documented hepatoprotective function. Pathway co-membership with CYCS in the "mitochondrial injury / ER stress" module; no direct interaction.

9. **CSF1R** — log2FC −1.98 (DOWN). Receptor for M-CSF, required for Kupffer cell self-maintenance. Its loss is biologically consistent with the resident-KC depletion program (Program 1).

10. **UBD + CXCL10 + TREM2 + MARCO module** — as a composite, these four genes form an interaction module in which UBD and CXCL10 share a common upstream IFN-γ/TNF-α driver, TREM2 and CXCL10 are co-expressed in TREM2+ LAMs in published scRNA-seq, and MARCO sits in the opposing resident-KC module. The relationships are **co-expression / pathway co-membership / opposing-population**, **not direct physical interactions**.

> *Note on directionality caveat:* TREM2 is the single largest signal in this dataset; even though its causal role in NASH has been demonstrated in mouse models, in bulk tissue this gene is principally a marker of a specific macrophage population whose abundance is changing. The dataset alone cannot separate this from a true increase in TREM2 transcription per cell.

---

## 4. Validation Priorities

### Priority 1 — TREM2+ macrophage dynamics as a biomarker of disease activity
- **Class:** Biomarker.
- **Why prioritize:** TREM2 is the strongest single signal and represents the most actionable cell-population shift in the dataset.
- **Dataset evidence:** log2FC +4.91 with FDR < 1e-8.
- **External evidence:** Multiple published human and murine scRNA-seq studies (Ramachandran et al. *Nature* 2019; Remmerie et al. *Cell Reports* 2020; Daemen et al. *Hepatology* 2021) place TREM2+ LAMs at the center of MASH.
- **Next step:** Multiplex immunofluorescence (TREM2, CD9, CD68, MARCO, TIMD4) on the same patient cohort to quantify population dynamics; serum soluble TREM2 ELISA as a candidate circulating biomarker.
- **Status:** **Supported hypothesis.** The association between TREM2+ LAMs and MASH is now considered established; the contribution of this dataset is replication, not discovery.

### Priority 2 — CXCL10 / CXCR3 axis as a therapeutic target
- **Class:** Therapeutic target.
- **Why prioritize:** CXCL10 is a well-validated human NASH biomarker and a tractable target.
- **Dataset evidence:** log2FC +3.46 with strong FDR; co-induction with UBD and TNFRSF12A supports a Th1/interferon-polarized niche.
- **External evidence:** CXCL10 is elevated in NASH patient serum and liver; CXCR3 antagonists are in clinical development for other inflammatory indications.
- **Next step:** Assess CXCL10 protein in serum paired with liver biopsies; evaluate CXCR3 inhibition in NASH-relevant preclinical models.
- **Status:** **Supported hypothesis** for biomarker; **exploratory hypothesis** as a therapeutic target in MASH specifically.

### Priority 3 — Resident Kupffer cell depletion as a pathogenic event
- **Class:** Mechanistic hypothesis.
- **Why prioritize:** Concurrent loss of MARCO, TIMD4, CD163, LYVE1, CSF1R, MRC1, and CD5L suggests a fundamental reorganization of the liver macrophage niche.
- **Dataset evidence:** All seven markers move in the same direction with consistent FDR.
- **External evidence:** Consistent with published fate-mapping studies showing embryonically derived Kupffer cells are outcompeted by monocyte-derived cells in NASH.
- **Next step:** Immunostaining for TIMD4 and MARCO in patient biopsies across MASH stages; fate-mapping experiments (e.g., Ms4a3-Cre lineage tracing) in murine NASH models.
- **Status:** **Supported hypothesis.**

### Priority 4 — TNFRSF12A (Fn14) / TWEAK axis as a fibrogenic driver
- **Class:** Therapeutic target.
- **Why prioritize:** Fn14 is a receptor with drug-development precedent; its upregulation in this dataset and known biology make it a high-yield candidate.
- **Dataset evidence:** log2FC +3.27, FDR < 1e-6.
- **External evidence:** Anti-TWEAK antibodies (e.g., RG7212, BIIB023) have been investigated clinically; TWEAK/Fn14 promotes HSC activation and fibrosis in preclinical models.
- **Next step:** Quantify Fn14 protein in liver and correlate with fibrosis stage; consider preclinical evaluation of Fn14 blockade in NASH models.
- **Status:** **Exploratory hypothesis** in MASH specifically; the protein is well-characterized elsewhere.

### Priority 5 — Mitochondrial tRNA / CYCS / MANF axis as a hepatocyte injury program
- **Class:** Mechanistic hypothesis (with biomarker implications).
- **Why prioritize:** The unusual pattern of multiple mitochondrial tRNAs upregulated alongside CYCS and MANF is internally consistent with lipotoxic mitochondrial stress and may indicate hepatocyte injury independent of inflammation.
- **Dataset evidence:** Five independent mitochondrial tRNAs (TRNK, TRNS1, TRNL2, TRNC, TRNY) with log2FC +2.7 to +4.1; CYCS +1.56; MANF +1.85.
- **External evidence:** Mitochondrial dysfunction is a recognized NASH feature; MANF is a documented UPR-responsive hepatoprotective factor.
- **Next step:** Quantitative PCR for mitochondrial DNA copy number to control for mtDNA-driven tRNA signal; immunostaining for MANF and cytochrome c release in patient biopsies.
- **Status:** **Exploratory hypothesis.** The mitochondrial tRNA signal in particular needs replication given that bulk-RNA tRNA quantification is methodologically fragile.

---

## 5. Evidence Grounding Summary

| Claim | Direct dataset evidence | Pathway / ontology | Independent replication | Strength |
|---|---|---|---|---|
| TREM2+ macrophage expansion | log2FC +4.91 | Hallmark inflammatory | Strong (multiple scRNA-seq) | Established |
| Resident KC depletion | MARCO, TIMD4, CD163, LYVE1, CSF1R all down | Reactome innate immunity | Strong | Supported |
| CXCL10-driven inflammation | log2FC +3.46 | Hallmark IFN-γ response | Strong | Established biomarker, exploratory therapeutic |
| Mitochondrial injury | CYCS +1.56, MANF +1.85, multiple mt-tRNAs | KEGG OXPHOS, apoptosis | Moderate | Exploratory |
| Fibrogenic priming via Fn14 | TNFRSF12A +3.27 | KEGG TNF signaling | Moderate | Exploratory |
| Sinusoidal capillarization | CDH5, LYVE1 down | Endothelial markers | Moderate | Supported |
| Complement homeostasis loss | CR1, CFP down | Reactome complement | Weak | Exploratory |

**Evidence-type caveats:** (a) TREM2 and the resident-KC marker set are *not* independent — they reflect opposing changes in the same cell population, so the "two independent programs" framing is somewhat overstated. (b) CXCL10 and UBD are genuinely independent IFN-induced genes and provide convergent support for the interferon/inflammation program. (c) The mitochondrial tRNA signal has no strong independent replication in this dataset; it should be considered a single line of evidence.

---

## 6. Limitations and Alternative Explanations

1. **Cell-composition confounding (most important).** The strongest signals — TREM2, MARCO, TIMD4, CD163, LYVE1, CSF1R — are all cell-population markers. Bulk RNA-seq cannot distinguish a transcriptional change within hepatocytes from a change in the relative number of Kupffer cells vs monocyte-derived macrophages. *How to investigate:* perform paired single-cell RNA-seq or multiplex immunofluorescence on the same biopsies; use computational deconvolution (CIBERSORTx, MuSiC) with a liver-specific reference.

2. **Disease stage and fibrosis heterogeneity.** MASH spans a spectrum from early inflammation to advanced fibrosis. The dataset's composite signal may mix stages, and stage-specific biology (e.g., fibrogenic programs in F3–F4) may be diluted. *How to investigate:* stratify by NAS and fibrosis stage; analyze differentially expressed genes per stage.

3. **Mitochondrial DNA copy-number variation.** Apparent mitochondrial tRNA upregulation (TRNK, TRNS1, TRNL2, TRNC, TRNY all up) may reflect increased mtDNA content per hepatocyte (a recognized feature of steatotic liver) rather than true transcriptional induction. *How to investigate:* qPCR of mtDNA/nDNA ratio in the same samples.

4. **Anatomical sampling variability.** MASH shows zonation (pericentral) injury; biopsies from different lobular zones will produce different transcriptomes. *How to investigate:* laser-capture microdissection or spatial transcriptomics.

5. **Poorly characterized non-coding transcripts.** A large fraction of the top hits are lncRNAs (LOC105377700, LOC107984754, NUCB1-AS1, MRPL1-AS1, MROH2B-DT, HSPA9-AS1), snoRNAs (SNORD140), miRNAs (MIR4647, MIR12136, MIR4426, MIR1244-1, MIR6717, MIR1825, MIR4721), and pseudogenes (UQCRBP1, CES1P2, GUSBP2, GLUD1P2). These dominate the top of the ranked list by FDR but cannot be biologically interpreted with current knowledge and should not be over-interpreted.

6. **Cross-platform and cohort confounding.** Without access to metadata on platform, library preparation, BMI, sex, age, diabetes status, or alcohol intake, batch effects and metabolic comorbidities cannot be excluded as drivers of any individual signal. *How to investigate:* require and report harmonized metadata; replicate in an independent cohort.

---

### Bottom-line synthesis
The dataset paints a biologically coherent picture of MASH as a disease in which **the hepatic macrophage compartment is fundamentally reorganized** (loss of resident Kupffer cells, emergence of TREM2+ LAMs), set against a backdrop of **interferon-driven inflammation (CXCL10, UBD)**, **fibrogenic priming (TNFRSF12A)**, and **mitochondrial injury (CYCS, MANF, mitochondrial tRNAs)**. The macrophage-remodeling program is the strongest and most externally validated finding; the mitochondrial and complement programs are exploratory and require additional controls for mtDNA copy number and cell composition before being treated as causal contributors.
